Suky Martinez1,2,3, Jermaine D Jones1, Laura Brandt1, Aimee N C Campbell1, Rebecca Abbott1, Sandra D Comer1. 1. Division of Substance Use Disorders, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York. 2. Translational Research Training Program in Addiction, City College of New York, Columbia University Irving Medical Center, New York, New York. 3. Gordon F. Derner School of Psychology, Adelphi University, Garden City, New York.
Abstract
BACKGROUND AND OBJECTIVES: Opioid-related overdose deaths in North America have increased drastically, partially due to the increased prevalence of illicitly manufactured fentanyl. The current study sought to assess the prevalence and intentionality of fentanyl use among individuals with opioid use disorder (OUD). METHODS: For this secondary analysis (study 1) we screened a total of 1118 urine samples from 316 participants with OUD from 2016 to 2019. Fentanyl knowledge and intentionality of use were assessed in a separate OUD sample (study 2; N = 33). RESULTS: In study 1, 34.6% of all urine samples tested positive for fentanyl. Overall, 149 (47.2%) participants provided more than or equal to one urine sample that tested fentanyl-positive, and 93 (29.4%) provided more than or equal to two fentanyl-positive samples. The number of fentanyl-positive samples, relative to the number of samples tested each year, increased by 330% from year 1 to 3. Study 2 found all participants had pre-existing knowledge that drugs may be adulterated with fentanyl, yet 67% were surprised by their own fentanyl-positive test result. DISCUSSION AND CONCLUSIONS: Like previous studies, our data indicate the high prevalence of fentanyl exposure and low perception of fentanyl-related risk among individuals with OUD, respectively, suggesting that opioid overdose harm reduction efforts may need to focus more on drug users' understanding of risks related to fentanyl use and adulteration of drugs. SCIENTIFIC SIGNIFICANCE: The current studies provide longitudinal data on fentanyl exposure prevalence and risk perception that is uniquely granular by assessing OUD treatment status, and by identifying potential associations between fentanyl exposure with the presence of other drug use and nonfatal overdose. (Am J Addict 2021;30:65-71).
BACKGROUND AND OBJECTIVES: Opioid-related overdose deaths in North America have increased drastically, partially due to the increased prevalence of illicitly manufactured fentanyl. The current study sought to assess the prevalence and intentionality of fentanyl use among individuals with opioid use disorder (OUD). METHODS: For this secondary analysis (study 1) we screened a total of 1118 urine samples from 316 participants with OUD from 2016 to 2019. Fentanyl knowledge and intentionality of use were assessed in a separate OUD sample (study 2; N = 33). RESULTS: In study 1, 34.6% of all urine samples tested positive for fentanyl. Overall, 149 (47.2%) participants provided more than or equal to one urine sample that tested fentanyl-positive, and 93 (29.4%) provided more than or equal to two fentanyl-positive samples. The number of fentanyl-positive samples, relative to the number of samples tested each year, increased by 330% from year 1 to 3. Study 2 found all participants had pre-existing knowledge that drugs may be adulterated with fentanyl, yet 67% were surprised by their own fentanyl-positive test result. DISCUSSION AND CONCLUSIONS: Like previous studies, our data indicate the high prevalence of fentanyl exposure and low perception of fentanyl-related risk among individuals with OUD, respectively, suggesting that opioid overdose harm reduction efforts may need to focus more on drug users' understanding of risks related to fentanyl use and adulteration of drugs. SCIENTIFIC SIGNIFICANCE: The current studies provide longitudinal data on fentanyl exposure prevalence and risk perception that is uniquely granular by assessing OUD treatment status, and by identifying potential associations between fentanyl exposure with the presence of other drug use and nonfatal overdose. (Am J Addict 2021;30:65-71).
Authors: Jacqueline E Goldman; Katherine M Waye; Kobe A Periera; Maxwell S Krieger; Jesse L Yedinak; Brandon D L Marshall Journal: Harm Reduct J Date: 2019-01-08
Authors: Nicholas C Peiper; Sarah Duhart Clarke; Louise B Vincent; Dan Ciccarone; Alex H Kral; Jon E Zibbell Journal: Int J Drug Policy Date: 2018-10-03
Authors: Jermaine D Jones; Aimee N Campbell; Laura Brandt; Verena E Metz; Suky Martinez; Melanie Wall; Thomas Corbeil; Howard Andrews; Felipe Castillo; Joanne Neale; John Strang; Stephen Ross; Sandra D Comer Journal: Drug Alcohol Depend Date: 2022-05-23 Impact factor: 4.852
Authors: Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley Journal: Biochem Pharmacol Date: 2021-10-19 Impact factor: 6.100
Authors: Neil B Varshneya; D Matthew Walentiny; Lea T Moisa; Teneille D Walker; Luli R Akinfiresoye; Patrick M Beardsley Journal: Pharmacol Biochem Behav Date: 2021-07-21 Impact factor: 3.697
Authors: R Michael Krausz; Jean N Westenberg; Nickie Mathew; George Budd; James S H Wong; Vivian W L Tsang; Marc Vogel; Conor King; Vijay Seethapathy; Kerry Jang; Fiona Choi Journal: Int J Ment Health Syst Date: 2021-12-20
Authors: Pouya Azar; Jean N Westenberg; Martha J Ignaszewski; James S H Wong; George Isac; Nickie Mathew; R Michael Krausz Journal: Addict Sci Clin Pract Date: 2022-04-05